Silence Therapeutics Plc ADR (SLN) Expected Move

Tracking the SLN expected move helps you see how far Silence Therapeutics Plc ADR's options market is pricing the stock to travel over a given period — whether that's the next day, week, or earnings cycle. Silence Therapeutics Plc ADR's expected move is derived directly from option premiums and gives you an objective range to plan trades, set strikes, and manage risk. Use our scanner to monitor the SLN expected move for this week's options, in real time.

The expected move is typically calculated from at-the-money straddle prices (or a blend of straddles and strangles) and represents roughly a one-standard-deviation range over the chosen timeframe. For SLN, comparing the implied expected move to actual realized moves over similar windows tells you whether the options market has historically overestimated or underestimated volatility. The SLN expected move for this week's options pricing is especially useful for short-dated traders, earnings players, and anyone selling premium who needs to know where the market thinks Silence Therapeutics Plc ADR is unlikely to go.

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera.

It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Iron condors, weekly premium sales, directional swing trades — they all live or die by where the market thinks the stock won't go. Our scanner tracks the SLN expected move across every expiration, benchmarks it against realized moves, and shows you when implied ranges are out of line with history. The Silence Therapeutics Plc ADR expected move for this week's options is the fastest read on short-term risk, which gives you a quick way to interpret what the options market thinks about SLN.